BioSpace News Archive

ANGLE plc, a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier , all resolutions were duly passed.

More than $274,000 in funding from NSF will be used to develop novel microscale arrays to improve development and delivery of novel therapies

IdentifySensors® Biologics, a leading developer of digital diagnostic technologies, announces the formation of the company’s new Clinical Studies Group, responsible for testing new diagnostic devices in preparation for FDA submissions.

Integra LifeSciences Holding Corporation, a leading global medical technology company, announced the completion of patient enrollment in the DuraSorb U.S. investigational device exemption clinical study for two-stage breast reconstruction.

Black Diamond Therapeutics, Inc., a clinical-stage precision oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with genetically defined cancers, announced that it has commenced an underwritten public offering of $75.0 million of shares of its common stock.

Spago Nanomedical AB announces that a preliminary analysis of data from the phase IIa clinical study SPAGOPIX-02 shows that SN132D has a good safety profile in patients with endometriosis.

Moberg Pharma AB hereby announces that the Decentralized Procedure has ended with a positive outcome and that MOB-015 is recommended for national approval in 13 European countries for the treatment of mild to moderate fungal infections of the nails in adults.

Neuronascent Inc., announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal of Motor Deficits in AAV-Alpha Synuclein Model, Leaving Alpha Synuclein Unchanged has been accepted for a poster presentation at the Alzheimer’s Association International Conference to be held in Amsterdam, Holland, on July 19, 2023.

Eton Pharmaceuticals, Inc, an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, announced that the U.S. Food and Drug Administration issued a Complete Response Letter in response to its New Drug Application for dehydrated alcohol injection for the treatment of methanol poisoning.

Panbela Therapeutics, Inc today announced the SWOG Cancer Research Network’s PACES S0820 Phase III trial passed a single planned futility analysis and will continue.